Cjc-1295 non DAC Jera Labs 10000IU

$30.00

Substance: CJC-1295Package: 10 kits (10000IU)

Category: Tag:

Description

2 mg (2000 mcg) Cjc-1295 non DAC Jera Labs 10000IU (drug affinity complex) for longer half-life

Cjc-1295 non DAC Jera Labs 10000IU is an hGH secretogue that is unique by way of an additional lysine molecule that is added to facilitate the DAC complex. This conjugation makes for a much longer half-life.  DAC CJC 1295 tends to have a very limited availability everywhere due to expense and difficulty to manufacture.  CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. Receptor grade: 98%+ pure 2000mcg / 2ml glass vial. THIS PRODUCT IS INTENDED FOR RESEARCH PURPOSES ONLY. CAN BE HARMFUL IF USED INAPPROPRIATELY.

In the healthy human body, large amounts of growth hormone are stored in the pituitary.  The cells within the pituitary release growth hormone in response to signalling by Cjc-1295 non DAC Jera Labs 10000IU (Growth Hormone Releasing Hormone), Ghrelin (of which GHRPs – Growth Hormone Releasing Peptides – are mimetics), and are inhibited from releasing these stores by Somatostatin.  GHRH and Ghrelin act on different populations of somatotropes (GH releasing cells).  GHRP/Ghrelin increases the number of somatotropes releasing GH but not the amount released by each cell;
GHRH affects both the number of secreting cells and – moreso – the amount they each secrete. [1] GHRH and Ghrelin are released in specific patterns that vary depending on event and environment: post-exercise, in response to slow wave sleep, in certain stages of life and physical development, and so on.

Most people (even the diseased) continue to possess the ability to make GH in the pituitary. The problem is in the signalling of the pituitary to release it (and make more). So yes CJC is meant to replace the external administration of GH in some (but not all) cases.Even most people with diseases that affect growth hormone secretion retain the ability to continue to make GH in their pituitaries.  The disease states and symptoms result, most typically, in altered (dysfunctional) GH release signalling and this also affects the ability of the pituitary to continue to make more GH.